Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Baylor College of Medicine
This study will enroll preterm infants who were scheduled to receive treatment for ROP by laser or Bevacizumab. We will observe the patients in the hospital for the cure of ROP until 54 weeks' postmenstrual age. We will check the changes of chemicals in the blood and observe short-term and long-term effects on visual system, brain and other body organs. Descriptive statistics from a two sample t-test or Fisher's exact test will be used to compare the short and long-term vision and neurological development outcomes. We predefined a statistical significance level p=0.05.
Age
0–0
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Premature infants who were scheduled to receive laser or BEvacizumab treatment for type I ROP .
You may not be if
1. Have unilateral or Bilateral ROP Stage 4 or 5 ROP;
2. Lack of signed consent by the parent or legal guardian.
Clareo Health | 39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity
